Results indicate that combination therapies utilizing hypomethylating agents promoted upregulation of HLA class I molecules and IFN gamma signaling pathways as well as increased tumor infiltration by CD8 + T cells, hallmarks for sensitivity to immunotherapy [44]. This evidence concerns the gene CD8A and neoplasm.